Volume 4, Issue 8 While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinic...

Volume 4, Issue 6. Linking high-risk populations like PWIDs (people who inject drugs) and MSM (men who have sex with men) to effective HIV care requires overcoming complex barriers unique to these groups. In this issue,

Volume 4, Issue 4. The incidence of the metabolic complications common in people with HIV infection — bone disease, weight gain, cardiovascular disease, and liver disease — is increasing as improved antiretroviral therapies create longer lifespans.

Volume 4, Issue 2. Recently approved treatment options and new antiviral therapies still under investigation — through case-based discussion, Dr. Ethel Weld from the Division of Clinical Pharmacology and Infectious Diseases at the Johns Hopkins Univers...

In The Clinic: Improving Outcomes in At-Risk Populations

Volume 3, Issue 8. In this podcast Drs. Allison Agwu evaluates the specific barriers to testing and entering into care among transsexual individuals, migrant and immigrant populations, and adolescents.

Volume 3, Issue 6. In this podcast about ART, Dr. Rachel Simmons from Boston University School of Medicine discusses recent research that may improve clinicians’ ability to more effectively and more safely manage their patients with HIV infection.

Volume 3, Issue 4. In this podcast, Dr. Douglas Krakower discusses pre-exposure prophylaxis and addresses provider and patient barriers to PrEP. Take our post-test to claim CME credits. To read a companion newsletter click here.

HIV: Management of Concomitant Conditions

HIV: Management of Concomitant Conditions